Teleflex (TFX)
(Delayed Data from NYSE)
$203.01 USD
+4.28 (2.15%)
Updated May 3, 2024 04:00 PM ET
After-Market: $203.03 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Brokerage Reports
Teleflex Incorporated [TFX]
Reports for Purchase
Showing records 161 - 180 ( 461 total )
Company: Teleflex Incorporated
Industry: Medical - Instruments
Comprehensive Technical and Fundamental Analysis for TFX.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Teleflex Incorporated
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Teleflex Incorporated
Industry: Medical - Instruments
Comprehensive Technical and Fundamental Analysis for TFX.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Teleflex Incorporated
Industry: Medical - Instruments
Company: Teleflex Incorporated
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Teleflex Incorporated
Industry: Medical - Instruments
Strategically Important Step to LT International Expansion
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Teleflex Incorporated
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Teleflex Incorporated
Industry: Medical - Instruments
Company: Teleflex Incorporated
Industry: Medical - Instruments
Company: Teleflex Incorporated
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Teleflex Incorporated
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Teleflex Incorporated
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Teleflex Incorporated
Industry: Medical - Instruments
Company: Teleflex Incorporated
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Teleflex Incorporated
Industry: Medical - Instruments
Final Rule Appears in Line with Our Base Case Assumption
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Teleflex Incorporated
Industry: Medical - Instruments
Company: Teleflex Incorporated
Industry: Medical - Instruments
UroLift Miss and Guidedown Likely the Primary Focus; Margins Driving Better EPS Though
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Teleflex Incorporated
Industry: Medical - Instruments
Hard to Explain UroLift Miss and Guidance Revision Just from COVID
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Teleflex Incorporated
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department